Patricia S. Andrews
Audit Committee
Ms. Andrews has served as a director of Geron since March 2026.
Background
Ms. Andrews currently serves as a member of the Board of Directors (BOD) of Glenmark Pharmaceuticals Limited, a global pharmaceutical company, and as a director of its wholly-owned subsidiary, Ichnos Glenmark Innovation (IGI), a clinical-stage oncology research and development company, positions she has held since August 2025. Since 2024, she has also served as a member of the BOD of Oncolytics Biotech Inc., a clinical-stage oncology company. Previously, she served as a member of the BOD and the Audit Committee of GlycoMimetics, Inc., a clinical-stage biopharmaceutical company focused on oncology, from June 2017 until its merger with Crescent Biopharma in June 2025. Ms. Andrews served as Chief Executive Officer (CEO) of Sumitomo Pharma Oncology, Inc. (formerly Boston Biomedical, Inc.), a clinical-stage biopharmaceutical company focused on the treatment of hematological malignancies and solid tumors, and as an Executive Officer of its parent company, Sumitomo Pharma Co., Ltd., from April 2017 to June 2023.
Ms. Andrews was also the Global Head of Oncology for Sumitomo Pharma Co., from June 2020 to June 2023. Ms. Andrews joined Boston Biomedical in November 2013 as Executive Vice President (EVP) and Chief Commercial Officer (CCO) and was promoted to Chief Operating Officer (COO) in 2015. From October 2008 to August 2012, Ms. Andrews served as EVP and CCO at Incyte Corporation. Prior to Incyte, Ms. Andrews held roles of increasing responsibility at Pfizer Inc. from 1991 to 2008, including as Vice President and General Manager of the U.S. Oncology Business Unit and Vice President, Specialty Markets. Ms. Andrews holds an M.B.A. with a focus on Finance from the University of Michigan (Ann Arbor) and a B.A. in History and Political Science from Brown University.